Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

Abbott begins new Intravascular Lithotripsy trial to improve outcomes in patients with coronary artery disease: Abbott Park, Illinois Wednesday, March 26, 2025, 15:00 Hrs [IST] Ab ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...